| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/08/2013 | WO2013114231A1 Treated apertures |
| 08/08/2013 | WO2013114185A1 Multilayer microincapsulated probiotic bacteria |
| 08/08/2013 | WO2013113820A1 Antibody-containing sustained-release formulation for ocular administration |
| 08/08/2013 | WO2013113767A1 Method for administration of a probiotic |
| 08/08/2013 | WO2013113690A1 Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine |
| 08/08/2013 | WO2013113130A1 Electrode sensor kit, electrode assembly, and topical preparation for establishing electrical contact with skin, use thereof, and method of electro-impedance tomography (eit) imaging using these |
| 08/08/2013 | WO2013089394A3 Composition of an aqueous solution of polymeric nanoparticles and method for preparing same |
| 08/08/2013 | WO2013026989A3 Liposome comprising at least one cholesterol derivative |
| 08/08/2013 | WO2012090070A8 Biodegradable drug delivery compositions |
| 08/08/2013 | WO2012015691A3 Recombinant lectins, binding-site modified lectins and uses thereof |
| 08/08/2013 | US20130204181 Dual-modal imaging-guided drug vehicle with ultrasound-triggered release function |
| 08/08/2013 | US20130204166 Custom designed microbubble contrast agents and techniques of ultrasound delivery optimized for gene therapy |
| 08/08/2013 | US20130203982 Cellulose interpolymers and method of oxidation |
| 08/08/2013 | US20130203869 Pyrroloquinoline quinone gel |
| 08/08/2013 | US20130203837 PREPARATION OF MICROVESICLE-siRNA COMPLEXES AND USE THEREOF IN AIDS TREATMENT |
| 08/08/2013 | US20130203834 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 08/08/2013 | US20130203833 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 08/08/2013 | US20130203796 Injectable flowable composition comprising buprenorphine |
| 08/08/2013 | US20130203723 Preparation for Improving Solubility of Poorly Soluble Drug |
| 08/08/2013 | US20130203721 Taste-masked powder for suspension compositions of methylprednisolone |
| 08/08/2013 | US20130203720 Testosterone gel and method of use |
| 08/08/2013 | US20130203602 Supported biologically active compounds |
| 08/08/2013 | US20130203169 Conditioned cell culture medium compositions and methods of use |
| 08/08/2013 | US20130202713 Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt |
| 08/08/2013 | US20130202712 Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease |
| 08/08/2013 | US20130202711 Substance-encapsulating vesicle and process for producing the same |
| 08/08/2013 | US20130202710 Pharmaceutical composition for the prolonged release of trimetazidine |
| 08/08/2013 | US20130202706 Nanostructured atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
| 08/08/2013 | US20130202705 Alcohol-resistant formulations |
| 08/08/2013 | US20130202703 Method for producing gardenia blue pigment |
| 08/08/2013 | US20130202700 Rapidly disintegrating coated tablets |
| 08/08/2013 | US20130202693 Oral Dosage Forms of Bendamustine |
| 08/08/2013 | US20130202691 Modified starch derivative-based matrix for colon targeting |
| 08/08/2013 | US20130202690 Encapsulated picoplatin |
| 08/08/2013 | US20130202688 Delayed release oral disintegrating pharmaceutical compositions of lansoprazole |
| 08/08/2013 | US20130202686 Liposome composition and process for production thereof |
| 08/08/2013 | US20130202684 Pegylated liposomes for delivery of immunogen encoding rna |
| 08/08/2013 | US20130202683 Topical formulations having enhanced bioavailability |
| 08/08/2013 | US20130202682 Synthetic matrix vesicles for biomimetic mineralization |
| 08/08/2013 | US20130202681 Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles |
| 08/08/2013 | US20130202680 Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate |
| 08/08/2013 | US20130202677 Patch |
| 08/08/2013 | US20130202675 Systems and methods for the fabrication of tissue patches |
| 08/08/2013 | US20130202674 Tissue patch |
| 08/08/2013 | US20130202673 Heterogeneous implantable devices for drug delivery |
| 08/08/2013 | US20130202669 Albumin fibers and fabrics and methods of generating and using same |
| 08/08/2013 | US20130202668 Personal Towelette with Cooling Composition for Relief of Heat Symptoms |
| 08/08/2013 | US20130202667 Hydrogel particle coated with lipid and method for manufacturing same |
| 08/08/2013 | US20130202663 Remedy |
| 08/08/2013 | US20130202662 o/w/o EMULSION CONTAINING LIGNAN COMPOUNDS AND COMPOSITION CONTAINING THE SAME |
| 08/08/2013 | US20130202661 Formulations of viloxazine |
| 08/08/2013 | US20130202658 Compositions Comprising Buprenorphine |
| 08/08/2013 | US20130202657 Foams or particles for applications such as drug delivery |
| 08/08/2013 | US20130202656 Systems and kits for the fabrication of tissue patches |
| 08/08/2013 | US20130202654 Topical Foam Composition |
| 08/08/2013 | US20130202636 Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins |
| 08/08/2013 | US20130202605 Protein sustained-release injectable formulation |
| 08/08/2013 | US20130202559 Use of Microvesicles in the Treatment of Medical Conditions |
| 08/08/2013 | US20130199519 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 08/08/2013 | DE102012002372A1 Konzentrat für eine Dialysierflüssigkeit und daraus hergestellte Dialysierflüssigkeit Concentrate for a dialysis fluid and derived dialysis fluid |
| 08/08/2013 | CA2857430A1 Wafer and capsule formulations with enhanced dissolution rates for fenofibrate |
| 08/08/2013 | CA2857082A1 Diethyl-[6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)- naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dysttrophy |
| 08/07/2013 | EP2623498A1 Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| 08/07/2013 | EP2623497A1 Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| 08/07/2013 | EP2623132A1 Temporal release of growth factors from 3d micro rod scaffolds for tissue regeneration |
| 08/07/2013 | EP2623103A1 Patch |
| 08/07/2013 | EP2623102A1 Transdermal absorption preparation |
| 08/07/2013 | EP2623100A1 Preparation for improving solubility of poorly soluble drug |
| 08/07/2013 | EP2623099A1 Composition and method for treating neurological disease |
| 08/07/2013 | EP2623097A1 Solid lipid nanoparticles including elastin-like polypeptides and use thereof |
| 08/07/2013 | EP2623096A2 Pharmaceutical composition with slow release of trimetazidine |
| 08/07/2013 | EP2623095A1 Injectable nanoparticulate olanzapine formulations |
| 08/07/2013 | EP2622969A1 High-purity mogrosides and process for their purification |
| 08/07/2013 | EP2622026A1 A process for treating sol-gel capsules |
| 08/07/2013 | EP2621588A2 Methods and compositions for disease treatment using inhalation |
| 08/07/2013 | EP2621541A2 Shape-controlled magnetic nanoparticles as t1 contrast agents for magnetic resonance imaging |
| 08/07/2013 | EP2621512A1 Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
| 08/07/2013 | EP2621509A2 Formulations of guanylate cyclase c agonists and methods of use |
| 08/07/2013 | EP2621500A2 Therapeutic use of a tlr agonist and combination therapy |
| 08/07/2013 | EP2621499A2 Methods for the treatment of allergic diseases |
| 08/07/2013 | EP2621498A2 Combination treatment for dermatological conditions |
| 08/07/2013 | EP2621497A2 Combination treatment for rosacea |
| 08/07/2013 | EP2621494A1 Use of magnesium stearate in dry powder formulations for inhalation |
| 08/07/2013 | EP2621488A1 Cationic dry powders |
| 08/07/2013 | EP2621487A2 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| 08/07/2013 | EP2621485A2 Low dose pharmaceutical composition comprising zanamivir |
| 08/07/2013 | EP2621484A1 Monovalent metal cation dry powders for inhalation |
| 08/07/2013 | EP2621480A1 Low molecular weight cationic lipids for oligonucleotide delivery |
| 08/07/2013 | EP2621479A1 Protective coatings for acidic active ingredients |
| 08/07/2013 | EP2621478A2 Method of preparing a dry powder from a water bacteria extract-concentrate |
| 08/07/2013 | EP2621477A1 Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| 08/07/2013 | EP2621476A1 Enteric coated, low- strength pancrelipase formulations |
| 08/07/2013 | EP2621475A1 Treatment of tinnitus and related auditory dysfunctions |
| 08/07/2013 | EP2621474A2 Emulsion method for preparing low residual solvent microparticles |
| 08/07/2013 | EP2621473A2 Method for removing residual organic solvent from microparticles |
| 08/07/2013 | EP2621472A1 Dry processing of atazanavir |
| 08/07/2013 | EP2621471A2 Pharmaceutical composition comprising deferasirox |
| 08/07/2013 | EP2621470A1 Process for preparing a chemical structure having a phase partition, capable of generating a specific fluorescence spectrum and uses thereof |
| 08/07/2013 | EP2621469A2 Cyclosporine emulsion |
| 08/07/2013 | EP2621468A2 Pharmaceutical composition |